Recovery from hypogonadism and male health in adult allogeneic stem cell transplantation

<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>There is a substantial lack of data about men`s health in adult allogeneic stem cell transplantation.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted prospective unicentric non‐interventional clinical study on men′s health with a follow‐up time of 1 year.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Between 11/2013 and 12/2015, we were able to include 27 patients. <jats:styled-content style="fixed-case">AML</jats:styled-content> was the most frequent underlying disease (25.9%), and we mainly used intermediate intense conditioning protocols (77.8%). Erectile dysfunction, loss of libido, and loss of efficiency were the most frequent symptoms of hypogonadism. At inclusion of the study, hypogonadism was already frequent. Primary hypogonadism was found in eight cases (29.6%) and secondary hypogonadism in one case (3.7%). We did not observe hypogonadism 6 months after inpatient treatment anymore, but there might still be the impairment of fertility because of still rising <jats:styled-content style="fixed-case">FSH</jats:styled-content> levels at the end of the observation period. There were no significant associations of hypogonadism with myeloablative conditioning or kind of donor. Interestingly, there is a significant association with nicotine abuse (<jats:italic>P</jats:italic> = .049).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>On the whole, male hypogonadism was found in one‐third of the patients who underwent allogeneic stem cell transplantation.</jats:p></jats:sec>